• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
23
Jun
2017

Senate Healthcare Overhaul Advances, Novartis Nails CV Study, Clovis Cashes In on PARP Win

/
Luke Timmerman
/
0
/
All
23 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Jun
2017

Repare Secures $68M Series A to Discover ‘Synthetic Lethal’ Cancer Drugs

/
Luke Timmerman
/
2
/
All, Cancer, Venture Capital
22 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Jun
2017

Rubius Snags $120M to Engineer Red Blood Cell Therapies Off The Shelf

/
Luke Timmerman
/
0
/
All, Venture Capital
21 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
Jun
2017

Plants in Space Might Be Trying to Tell Us Something Cautionary About Precision Medicine

/
Kyle Serikawa
/
0
/
All, Genomics
20 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Jun
2017

An American Sickness: A Skillful Deconvolution of the U.S. Healthcare Mess

/
Luke Timmerman
/
2
/
All, The Edge
19 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
16
Jun
2017

Supreme Court Speeds Biosimilars, Clancy’s Lucrative Switch, & Apple Sniffs Around Health Records

/
Luke Timmerman
/
0
/
All
16 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
15
Jun
2017

Do’s and Don’ts for Startup Boards

/
Robert More
/
4
/
All, Venture Capital
15 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
12
Jun
2017

Long-Distance Relationships in Biotech Startups: How to Make Them Work

/
Luke Timmerman
/
0
/
All, The Edge
12 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Jun
2017

FDA Drops Opioid Hammer, Collins Stays at NIH, & Pfizer’s Relentless Ratcheting

/
Luke Timmerman
/
0
/
All
09 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Jun
2017

ASCO Takeaways A-Z (Part 2)

/
Luke Timmerman
/
0
/
All, Cancer
09 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
8
Jun
2017

ASCO Takeaways From A-Z (Part 1)

/
Luke Timmerman
/
1
/
All, Cancer
08 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Jun
2017

ASCO Notebook: Observations on Cancer R&D from Foundation Medicine, Halozyme, Blueprint, Nektar

/
Luke Timmerman
/
2
/
All, Cancer
05 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Jun
2017

State AGs Pull Knives on Pharma, Grail Grows by Acquisition, CRISPR Jitters

/
Luke Timmerman
/
0
/
All
02 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
1
Jun
2017

Atlas Venture Lures Rising Star Away from Polaris

/
Luke Timmerman
/
2
/
All, People, Venture Capital
01 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
31
May
2017

Parting Thoughts from Genzyme CEO David Meeker

/
Leora Schiff
/
0
/
All, People
31 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
26
May
2017

Alexion Expose, a Historic First at FDA, and Puma’s Come-From-Behind Victory

/
Luke Timmerman
/
0
/
All
26 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
25
May
2017

12 VCs Who Matter, But You Never Read About

/
Luke Timmerman
/
0
/
All, People, The Edge, Venture Capital
25 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
May
2017

A Biotech Pioneer Leaves Us, Verily Hires Ex-FDA Commish, Amazon Prowling Pharma

/
Luke Timmerman
/
0
/
All
19 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
May
2017

Former Sarepta CEO Gets $15M From Hedge Fund for Startup Incubator

/
Luke Timmerman
/
3
/
All
18 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
May
2017

A Former Lieutenant’s Tribute to Henri Termeer

/
Chris Rivera
/
1
/
All
18 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 62 63 64 65 66 … 80 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial

View More Testimonials ➛

© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder